Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 7, 2010

View Archived Issues

INCB-7839 improves response to trastuzumab in metastatic HER2+ breast cancer

[131I]-Basiliximab is safe and induces responses in patients with refractory lymphoma

DanDrit's MelCancerVac cancer vaccine active in phase II trial in colorectal cancer

FDA grants emergency use authorization to Cepheid's Xpert Flu A Panel

Phase II investigation of diabetes treatment EGT-0001442 begins

EXC-001 enters phase II trials for improving surgery-related scar appearance

Novel inhibitors of IAP inhibitors claimed by the University of Michigan

IRM discovers novel ALK inhibitors for cancer therapy

Glaxo Wellcome discloses NK1 receptor antagonists for sleep disorders

Novel erythromycin derivatives for respiratory disorders in development at GSK

Pearl reports results from phase IIa trial of formoterol inhalation aerosol in COPD

Dendritic cells do not enhance activity of canarypox-HIV vaccine

Dh-404 reduces oxidative stress and may be beneficial to treat heart disease

UK scientists divulge novel B-Raf kinase inhibitors for cancer therapy

Keryx announces SPA agreement with FDA on phase III Zerenex trials in ESRD

Luitpold acquires PharmaForce

Novartis agreement to supply rhPDGF-BB to BioMimetic amended

Gilead's Quad regimen meets primary objective in phase II trial in HIV-infected adults

Takeda discloses novel SMO antagonists for cancer therapy

Novo Nordisk and Combine to collaborate in the field of autoimmune diseases

Phase II trial of AZX-100 for dermal scarring completes enrollment

FDA accepts development path for ARYx Therapeutics' anticoagulant tecarfarin

Encouraging top-line results reported from ACCORD COPD I study of aclidinium

BioMarin's amifampridine phosphate approved in the EU for LEMS

OncoMethylome and Roche to collaborate on phase III Avastin trial in glioblastoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...